, Tracking Stock Market Picks
Enter Symbol:

up 39.34 %

QUESTOR PHARMACEUTCL (QCOR) upgraded to Buy by BofA/Merrill

Posted on: Wednesday,  Aug 21, 2013  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Buy QUESTOR PHARMACEUTCL (NASDAQ: QCOR) on 08/21/2013, when the stock price was $67.17. Since
then, QUESTOR PHARMACEUTCL has gained 39.35% as of 08/14/2014's recent price of $93.60.
If you would have followed this BofA/Merrill's recommendation on QCOR, you would have gained 39.34% of your investment in 358 days.

Questcor Pharmaceuticals, Inc. (Questcor) markets H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (MS), and the treatment of nephrotic syndrome. H.P. Acthar Gel (Acthar) is not indicated for, but is also used in treating patients with infantile spasms (IS). The Company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. As of December 31, 2008, Acthar was approved in the United States for the treatment of exacerbations associated with MS, nephrotic syndrome and many other conditions with an inflammatory component.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/21/2013 8:25 AM Buy
as of 12/13/2013
1 Week up  1.29 %
1 Month down  -15.03 %
3 Months down  -15.47 %
1 YTD up  47.37 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/21/2013 8:25 AM Hold
7/13/2012 8:25 AM Buy

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy